Thyroid eye disease (TED) is seen most commonly with Graves’ disease Symptoms include diplopia, eyelid erythema and retraction, and soreness and grittiness of eyes with increased watering. Severe cases (3 - 5%) may present with pain, corneal ulceration, optic nerve compression and partial/total loss of vision.

  Corticosteroids are the primary treatment for active phase TED, although there is risk of adverse effects such as weight gain, hypertension and immunosuppression with long-term, high-dose use.

  We will discuss a patient history with TED before, during and after treatment with tocilizumab and steroids Tocilizumab is current treatment options for moderate-to-severe.

  Given the role in the pathogenesis of TED of interleukin (IL)-6 expression in adipocytes, fibroblasts and macrophages, the proposed theory is that inhibition of IL-6 by tocilizumab may be an effective treatment in TED by directly reducing the inflammatory response.

Keywords: Thyroid; Eye Disease

References

1. The  European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the  (2016).
2. Graves’ ophthalmopathy. N Engl J Med
3. publication/41562276_Graves'_ophthalmopathy_N_Engl_J_-Med-Clinical Response to -Tocilizumab in Severe Thyroid Eye Disease
4. publication/303893349_Clinical_Response_to_Tocilizumab_in_Severe_Thyroid_Eye_Disease

Citation

Citation: Bashir Alnajjar. “Thyroid Eye Disease (Ted) Management: A Case Report”. Acta Scientific Ophthalmology 3.2 (2020): 40-44.

Copyright

Copyright: © 2020 Bashir Alnajjar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.